Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Study: Cancer stem-like cells are maintained by MTHFD2 mitochondrial metabolic enzyme

Study: Cancer stem-like cells are maintained by MTHFD2 mitochondrial metabolic enzyme

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Study suggests new target to treat prostate cancer

Study suggests new target to treat prostate cancer

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Targeted therapy appears to be more effective in preventing lung cancer recurrence

Targeted therapy appears to be more effective in preventing lung cancer recurrence

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

Penn studies provide new understanding of lung cancer progression and prevention

Penn studies provide new understanding of lung cancer progression and prevention

Researchers identify new way to prevent chemotherapy resistance in lung and breast cancers

Researchers identify new way to prevent chemotherapy resistance in lung and breast cancers

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Study highlights racial/ethnic disparities in genomic sequencing

Study highlights racial/ethnic disparities in genomic sequencing

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Post-progression afatinib exposure boosts NSCLC outcomes

Post-progression afatinib exposure boosts NSCLC outcomes

Lancet study compares prices of new cancer drugs in high-income countries

Lancet study compares prices of new cancer drugs in high-income countries